Financing ·
First Tracks Biotherapeutics completes $200M private placement
TRAXFirst Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics completed a private placement raising $200 million in gross proceeds. The transaction brings the company's pro forma cash position to approximately $343 million, up from $155.6 million reported as of September 30, 2026. This capital raise supports ongoing clinical development for its lead candidate ANB033 in celiac disease and eosinophilic esophagitis, with late-stage trials anticipated to begin in 2027. The company also provided a business update highlighting positive Phase 1b data for ANB033 and enrollment completion for the mucosal healing cohort.